Tuberculosis (TB) is an infectious disease, particularly preventable in children using the Bacillus Calmette-Guérin (BCG) attenuated vaccine. Individuals with strong immune systems can safely receive the BCG vaccine; however, certain factors such as age, immune system problems, vaccine dose, and injection route can cause side effects. Mild local reactions and ulceration at the intradermal injection site are common after BCG vaccination. However, in individuals with weakened immune systems, serious complications such as suppurative lymphadenitis, osteitis, or disseminated BCG disease (BCGosis) may develop. Therefore, the BCG vaccine should be carefully considered in individuals infected with human immunodeficiency virus (HIV) and patients with primary immunodeficiency disorder (PID). Treatment methods depend on the severity of the condition. In cases of uncomplicated injection site ulceration and minor, non-suppurative lymphadenopathy, local wound care and observation are conservative treatments. However, management approaches for deep or disseminated disease include surgical interventions and antimycobacterial therapy in addition to immunological evaluation. Furthermore, while hematopoietic stem cell transplantation may be considered in some PID patients, urgent enzyme replacement therapy using polyethylene glycol–modified adenosine deaminase (ADA) is necessary in patients with ADA deficiency. In conclusion, the BCG vaccine is a powerful tool in preventing TB, especially in childhood, and is safe in people with healthy immune systems. However, in individuals with any immune system–related disease, the administration of this attenuated vaccine should be evaluated by specialist physicians, and immediate intervention should be sought in case of serious side effects.
Citation: Sezer Okay. Complications related to Bacillus Calmette-Guérin vaccine and management approaches: A review[J]. AIMS Allergy and Immunology, 2026, 10(3): 184-198. doi: 10.3934/Allergy.2026013
Tuberculosis (TB) is an infectious disease, particularly preventable in children using the Bacillus Calmette-Guérin (BCG) attenuated vaccine. Individuals with strong immune systems can safely receive the BCG vaccine; however, certain factors such as age, immune system problems, vaccine dose, and injection route can cause side effects. Mild local reactions and ulceration at the intradermal injection site are common after BCG vaccination. However, in individuals with weakened immune systems, serious complications such as suppurative lymphadenitis, osteitis, or disseminated BCG disease (BCGosis) may develop. Therefore, the BCG vaccine should be carefully considered in individuals infected with human immunodeficiency virus (HIV) and patients with primary immunodeficiency disorder (PID). Treatment methods depend on the severity of the condition. In cases of uncomplicated injection site ulceration and minor, non-suppurative lymphadenopathy, local wound care and observation are conservative treatments. However, management approaches for deep or disseminated disease include surgical interventions and antimycobacterial therapy in addition to immunological evaluation. Furthermore, while hematopoietic stem cell transplantation may be considered in some PID patients, urgent enzyme replacement therapy using polyethylene glycol–modified adenosine deaminase (ADA) is necessary in patients with ADA deficiency. In conclusion, the BCG vaccine is a powerful tool in preventing TB, especially in childhood, and is safe in people with healthy immune systems. However, in individuals with any immune system–related disease, the administration of this attenuated vaccine should be evaluated by specialist physicians, and immediate intervention should be sought in case of serious side effects.
| [1] | World Health OrganizationGlobal tuberculosis report 2025 (2025). Available from: https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/tb-reports/global-tuberculosis-report-2025 |
| [2] |
Ong RYL, Chan SB, Chew SJ, et al. (2020) Disseminated Bacillus-Calmette-Guérin infections and primary immunodeficiency disorders in Singapore: A single center 15-year retrospective review. Int J Infect Dis 97: 117-125. https://doi.org/10.1016/j.ijid.2020.05.117 
|
| [3] |
Norouzi S, Aghamohammadi A, Mamishi S, et al. (2012) Bacillus Calmette-Guérin (BCG) complications associated with primary immunodeficiency diseases. J Infect 64: 543-554. https://doi.org/10.1016/j.jinf.2012.03.012
|
| [4] |
Rezai MS, Khotaei G, Mamishi S, et al. (2008) Disseminated Bacillus Calmette-Guerin infection after BCG vaccination. J Trop Pediatr 54: 413-416. https://doi.org/10.1093/tropej/fmn053
|
| [5] |
Elsidig N, Alshahrani D, Alshehri M, et al. (2015) Bacillus Calmette-Guérin vaccine related lymphadenitis in children: Management guidelines endorsed by the Saudi Pediatric Infectious Diseases Society (SPIDS). Int J Pediatr Adolesc Med 2: 89-95. https://doi.org/10.1016/j.ijpam.2015.05.003
|
| [6] |
Liu Q, Dai X, Wei S (2025) BCGitis and BCGosis: Clinical spectrum, immunological mechanisms, and risk management. Vaccines 13: 1179. https://doi.org/10.3390/vaccines13121179
|
| [7] |
Huang S, Cheng F, Guo H, et al. (2025) Clinical characteristics and outcomes of severe adverse reactions to Bacille Calmette-Guérin (BCG) vaccination in China: A single-center retrospective study. Sage Open Pediatr 12. https://doi.org/10.1177/30502225251346345
|
| [8] |
Tural-Kara T, Ozdemir H, Erat T, et al. (2017) Local cutaneous complications after Bacille Calmette-Guerin vaccine: Experience of a single center. Int J Clin Pediatr 6: 37-41. https://doi.org/10.14740/ijcp279w
|
| [9] | Elitok GK (2025) Management of Bacille Calmette-Guérin vaccine adverse event: Case report. Bagcilar Med Bull 10: 320-322. https://doi.org/10.4274/BMB.galenos.2025.46220 |
| [10] |
Loh ACE, Kua PHJ, Tan ZL (2019) Erythema and induration of the Bacillus Calmette-Guérin site for diagnosing Kawasaki disease. Singapore Med J 60: 89-93. https://doi.org/10.11622/smedj.2018084
|
| [11] |
Villanueva P, Crawford NW, Croda MG, et al. (2023) Factors influencing scar formation following Bacille Calmette-Guérin (BCG) vaccination. Heliyon 9: e15241. https://doi.org/10.1016/j.heliyon.2023.e15241
|
| [12] |
Eregie CO (1997) Ulceration of a previously healed BCG scar in suspected disseminated BCG infection. Ann Trop Paediatr 17: 135-139. https://doi.org/10.1080/02724936.1997.11747876
|
| [13] |
Ghattaura A, Eley KA, Molenaar E, et al. (2009) A case of extensive ulcerating vasculitis following a BCG vaccination. J Plast Reconstr Aesthet Surg 62: e286-e289. https://doi.org/10.1016/j.bjps.2007.11.031
|
| [14] |
Castresana G, Arango CA (2020) BCG vaccine-related lymphadenitis and BCGitis. Consultant 60: e8. https://doi.org/10.25270/con.2020.03.00017
|
| [15] |
Goraya JS, Virdi VS (2002) Bacille Calmette-Guérin lymphadenitis. Postgrad Med J 78: 327-329. https://doi.org/10.1136/pmj.78.920.327
|
| [16] |
Baek SO, Ko HS, Han HH (2017) BCG vaccination-induced suppurative lymphadenitis: Four signs to pay attention to. Int Wound J 14: 1385-1387. https://doi.org/10.1111/iwj.12755
|
| [17] |
Rangesh S, Vaidya PC, Mehra N, et al. (2022) Incidence of lymphadenitis following Bacillus Calmette-Guérin (BCG) vaccination in north Indian children. Indian J Tuberc 69: 596-601. https://doi.org/10.1016/j.ijtb.2021.09.008
|
| [18] |
Villanueva P, Wadia U, Crawford N, et al. (2022) Revaccination with Bacille Calmette-Guérin (BCG) is associated with an increased risk of abscess and lymphadenopathy. NPJ Vaccines 7: 6. https://doi.org/10.1038/s41541-021-00421-5
|
| [19] |
Vaghasiya VL, Nasit JG, Rupavatiya B, et al. (2024) The spectrum of cytological findings in patients with BCG lymphadenitis: A series of 13 cases. Ann Diagn Pathol 69: 152260. https://doi.org/10.1016/j.anndiagpath.2023.152260
|
| [20] | Nazir Z, Qazi SH (2005) Bacillus Calmette-Guerin (BCG) lymphadenitis-changing trends and management. J Ayub Med Coll Abbottabad 17: 16-18. |
| [21] |
Miyamura T, Egashira S, Yoshino Y, et al. (2019) Papulonecrotic tuberculid after Bacillus Calmette-Guérin (BCG) vaccination with lung infiltration that mimics disseminated BCG infection. J Dermatol 46: e267-e268. https://doi.org/10.1111/1346-8138.14819
|
| [22] |
Parmar NV, Al Falasi A, Almualla A (2021) Bacillus Calmette-Guérin vaccine-induced lupus vulgaris in a 3-year-old child. An Bras Dermatol 96: 636-638. https://doi.org/10.1016/j.abd.2020.07.022
|
| [23] |
Adalı Ruşen Y, Mungan U, Yörükoğlu K (2025) Exploring the role of granuloma formation in the prognosis of BCG-treated bladder carcinoma. Bull Urooncol 24: 75-79. https://doi.org/10.4274/uob.galenos.2025.2025.3.1
|
| [24] |
Hung TK, Leung D, Duque JSR, et al. (2022) Bacillus Calmette-Guérin Scar erythema in a 14-year-old girl post-BNT162b2 vaccination. Pediatr Int 64: e15090. https://doi.org/10.1111/ped.15090
|
| [25] | Lopatynsky-Reyes EZ, Acosta-Lazo H, Ulloa-Gutierrez R, et al. (2021) BCG scar local skin inflammation as a novel reaction following mRNA Covid-19 vaccines in two international healthcare workers. Cureus 13: e14453. https://doi.org/10.7759/cureus.14453 |
| [26] |
Günaydın SD, Atakan N (2023) Bacillus Calmette-Guerin (BCG) site reaction after Coronavirus Disease 2019 (COVID-19) mRNA vaccination. Indian J Dermatol 68: 355. https://doi.org/10.4103/ijd.ijd_64_22
|
| [27] |
Noishiki C, Hayasaka Y, Yoshida R, et al. (2023) Over 90% of childhood BCG vaccine-induced keloids in Japan occur in women. Dermatol Ther 13: 1137-1147. https://doi.org/10.1007/s13555-023-00916-0
|
| [28] |
Han TI, Kim IO, Kim WS, et al. (2000) Disseminated BCG infection in a patient with severe combined immunodeficiency. Korean J Radiol 1: 114-117. https://doi.org/10.3348/kjr.2000.1.2.114
|
| [29] |
Lin WL, Chiu NC, Lee PH, et al. (2015) Management of Bacillus Calmette-Guérin osteomyelitis/osteitis in immunocompetent children—A systematic review. Vaccine 33: 4391-4397. https://doi.org/10.1016/j.vaccine.2015.07.039
|
| [30] |
Vaisban E, Melamed-Snapir Y, Braester A, et al. (2005) Bone marrow fibrosis and caseating granulomas associated with intravesicular BCG treatment. Eur J Intern Med 16: 301-303. https://doi.org/10.1016/j.ejim.2004.11.015
|
| [31] | French CG, Hickey L, Bell DG (2001) Caseating granulomas on the glans penis as a complication of Bacille Calmette-Guérin intravesical therapy. Rev Urol 3: 36-38. |
| [32] |
Botaro MH, Maria E, Silva J, et al. (2025) BCG vaccination in children with severe combined immunodeficiency in a tertiary center: Evaluation of complications and risks. J Pediatr 101: 224-230. https://doi.org/10.1016/j.jped.2024.09.008
|
| [33] |
Jafari L, Hamidieh AA, Behfar M, et al. (2023) Effect of early Bacillus Calmette-Guerin vaccination of pediatric severe combined immunodeficiency patients on the outcome of hematopoietic stem cell transplantation using a reduced-intensity conditioning regimen. Transplant Cell Ther 29: 188.e1-188.e8. https://doi.org/10.1016/j.jtct.2022.12.007
|
| [34] |
Roxo-Junior P, Silva J, Andrea M, et al. (2013) A family history of serious complications due to BCG vaccination is a tool for the early diagnosis of severe primary immunodeficiency. Ital J Pediatr 39: 54. https://doi.org/10.1186/1824-7288-39-54
|
| [35] |
Frankel H, Byberg S, Bjerregaard-Andersen M, et al. (2016) Different effects of BCG strains—A natural experiment evaluating the impact of the Danish and the Russian BCG strains on morbidity and scar formation in Guinea-Bissau. Vaccine 34: 4586-4593. https://doi.org/10.1016/j.vaccine.2016.07.022
|
| [36] | Siroosbakht S, Rezakhaniha B (2019) Complications of Bacillus Calmette-Guérin vaccination at a university hospital in Iranian neonates. J Compr Ped 10: e67098. https://doi.org/10.5812/compreped.67098 |
| [37] |
Jamil H, Sama G, Nohri AR, et al. (2025) Medical error in paediatric vaccination: Case report of accidental ONCO-BCG administration in neonates. J Health Wellness Community Res 3: e190. https://doi.org/10.61919/w4sn7v08
|
| [38] |
Al-Maqbali AA, Al-Maani AS (2016) The adverse events, signs, and management of neonatal Bacillus Calmette-Guérin vaccine overdose. Oman Med J 31: 315-317. https://doi.org/10.5001/omj.2016.61
|
| [39] |
Chetan C, Patra S, Singh SK, et al. (2023) Double BCG vaccination in a neonate: Implications, management and prevention. BMJ Case Rep 16: e256766. https://doi.org/10.1136/bcr-2023-256766
|
| [40] | World Health OrganizationWHO TB Knowledge Sharing Platform (2026). Available from: https://tbksp.who.int/en/node/2051 |
| [41] |
Wei SH, Ho WC, Chen YT, et al. (2018) The management and outcome of Bacillus Calmette-Guérin vaccine overdose. Pediatr Neonatol 59: 208-210. https://doi.org/10.1016/j.pedneo.2017.07.004
|
| [42] |
Qureshi S, Ahmad K, Fatima P, et al. (2019) Outcome of inadvertent high dose BCG administration in newborns at a tertiary care hospital, Karachi—Case series. PLoS One 14: e0219324. https://doi.org/10.1371/journal.pone.0219324
|
| [43] |
Puliyel JM, Hughes A, Chiswick ML, et al. (1996) Adverse local reactions from accidental BCG overdose in infants. BMJ 313: 528-529. https://doi.org/10.1136/bmj.313.7056.528
|
| [44] |
Pasteur MC, Hall DR (2001) The effects of inadvertent intramuscular injection of BCG vaccine. Scand J Infect Dis 33: 473-474. https://doi.org/10.1080/00365540152029981
|
| [45] |
Buyukoglan H, Gulmez I, Tutar N, et al. (2011) Gluteal abscess: An unusual complication of Bacille Calmette-Guérin. Ann Thorac Med 6: 235-236. https://doi.org/10.4103/1817-1737.84780
|
| [46] |
Yaşöz G, Belet N, Şensoy G (2014) Overdose and intramuscular administration of Bacille Calmette-Guerin vaccine in a 2-month-old infant. Turk J Pediatr 56: 669-672.
|
| [47] | Hesseling AC, Caldwell J, Cotton MF, et al. (2009) BCG vaccination in South African HIV-exposed infants--risks and benefits. S Afr Med J 99: 88-91. |
| [48] | World Health OrganizationSafety of BCG vaccine in HIV-infected children (2007). Available from: https://www.who.int/groups/global-advisory-committee-on-vaccine-safety/topics/bcg-vaccines |
| [49] | World Health OrganizationChildren living with HIV and neonates (2026). Available from: https://tbksp.who.int/en/node/2050 |
| [50] |
Rabie H, Frigati L, Hesseling AC, et al. (2015) Tuberculosis: Opportunities and challenges for the 90-90-90 targets in HIV-infected children. J Int AIDS Soc 18: 20236. https://doi.org/10.7448/IAS.18.7.20236
|
| [51] |
Dieye TN, Ndiaye BP, Dieng AB, et al. (2013) Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects. PLoS One 8: e67177. https://doi.org/10.1371/journal.pone.0067177
|
| [52] | Juzi JT, Sidler D, Moore SW (2008) Surgical management of BCG vaccine-induced regional axillary lymphadenitis in HIV-infected children. S Afr J Surg 46: 52-55. |
| [53] |
McCusker C, Upton J, Warrington R (2018) Primary immunodeficiency. Allergy Asthma Clin Immunol 14: 61. https://doi.org/10.1186/s13223-018-0290-5
|
| [54] |
Xia L, Yang Y, Li XY, et al. (2026) Primary immunodeficiency diseases with BCG-induced diseases: A 15-year longitudinal cohort study. J Clin Immunol 46: 30. https://doi.org/10.1007/s10875-026-01996-1
|
| [55] |
Soyak Aytekin E, Keskin A, Tan C, et al. (2021) Differential diagnosis of primary immunodeficiency in patients with BCGitis and BCGosis: A single-centre study. Scand J Immunol 94: e13084. https://doi.org/10.1111/sji.13084
|
| [56] |
Ozsezen B, Yalçın E, Ademhan Tural D, et al. (2022) Antimycobacterial prophylaxis regarding Bacillus Calmette-Guérin-associated complications in children with primary immunodeficiency. Respir Med 200: 106919. https://doi.org/10.1016/j.rmed.2022.106919
|
| [57] |
Xia L, Liu XH, Yuan Y, et al. (2022) An updated review on MSMD research globally and a literature review on the molecular findings, clinical manifestations, and treatment approaches in China. Front Immunol 13: 926781. https://doi.org/10.3389/fimmu.2022.926781
|
| [58] |
Aranda CS, Guimarães RR, de Gouveia-Pereira Pimentel M (2021) Combined immunodeficiencies. J Pediatr 97: S39-S48. https://doi.org/10.1016/j.jped.2020.10.014
|
| [59] |
Peters NE, Shields AM, Hambleton S, et al. (2025) Learning from inborn errors of immunity and secondary immune deficiencies about vaccine immunogenicity, efficacy, and safety. Clin Exp Immunol 219: uxaf059. https://doi.org/10.1093/cei/uxaf059
|
| [60] |
Jiao Y, Li Q, Chen Z, et al. (2025) Severe combined immunodeficiency with BCG-osis by salvage therapy with allogeneic hematopoietic stem cell transplantation: Cases report and literature review. BMC Pediatr 25: 768. https://doi.org/10.1186/s12887-025-06127-0
|
| [61] | Chan WM, Kwan YW, Leung CW (2011) Management of Bacillus Calmette-Guérin lymphadenitis. HK J Paediatr 16: 85-94. |
| [62] |
Mahdaviani SA, Fallahi M, Jamee M, et al. (2022) Effective anti-mycobacterial treatment for BCG disease in patients with Mendelian Susceptibility to Mycobacterial Disease (MSMD): A case series. Ann Clin Microbiol Antimicrob 21: 8. https://doi.org/10.1186/s12941-022-00500-y
|
| [63] |
Cocchi N, Jacobsen EM, Hoenig M, et al. (2022) BCG disease in SCID: Three decades of experience in a pediatric transplant center. J Clin Immunol 42: 195-198. https://doi.org/10.1007/s10875-021-01143-y
|
| [64] |
Laberko A, Yukhacheva D, Rodina Y, et al. (2020) BCG-related inflammatory syndromes in severe combined immunodeficiency after TCRαβ+/CD19+ depleted HSCT. J Clin Immunol 40: 625-636. https://doi.org/10.1007/s10875-020-00774-x
|
| [65] |
Canarutto D, Oltolini C, Barzaghi F, et al. (2023) Outcome of BCG vaccination in ADA-SCID patients: A 12-patient series. Biomedicines 11: 1809. https://doi.org/10.3390/biomedicines11071809
|
| [66] |
BrzeziŃska SA, Bielecka T, Zabost A, et al. (2020) Molecular methods in diagnostics of post-BCG vaccine adverse events. Cent Eur J Immunol 45: 130-135. https://doi.org/10.5114/ceji.2020.97900
|
| [67] | Martinson T, Hare CB, Kirmaier A, et al. (2025) Disseminated BCGosis after intravesical BCG installation for bladder cancer. Case Rep Infect Dis 2025: 9532859. https://doi.org/10.1155/crdi/9532859 |
| [68] |
Inauen J, Geake J, Sawka A, et al. (2025) A clinical case series of BCGosis as a rare complication of intravesical BCG. Clin Genitourin Cancer 23: 102271. https://doi.org/10.1016/j.clgc.2024.102271
|
Figures(3)
Sezer Okay. Complications related to Bacillus Calmette-Guérin vaccine and management approaches: A review[J]. AIMS Allergy and Immunology, 2026, 10(3): 184-198. doi: 10.3934/Allergy.2026013
DownLoad: